{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T16:11:08Z","timestamp":1765296668525,"version":"3.46.0"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Wuxi Health Commission","award":["FYKY202304"],"award-info":[{"award-number":["FYKY202304"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"DOI":"10.1186\/s12957-025-04098-1","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T14:40:19Z","timestamp":1765291219000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mapping the landscape of ovarian metastases of gastric cancer: insights, trends, and emerging perspectives"],"prefix":"10.1186","volume":"23","author":[{"given":"Liping","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tong","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuqing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,9]]},"reference":[{"key":"4098_CR1","doi-asserted-by":"publisher","unstructured":"Treatment strategy and prognostic factors for Krukenberg tumors of gastric origin. Report of a 10-year single-center experience from China. | J Clin Oncology[EB\/OL] [2024-12-18]. https:\/\/doi.org\/10.1200\/JCO.2018.36.4_suppl.52","DOI":"10.1200\/JCO.2018.36.4_suppl.52"},{"issue":"1","key":"4098_CR2","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s40644-023-00584-5","volume":"23","author":"ZHANG Q W","year":"2023","unstructured":"ZHANG Q W, YANG P P, GAO Y J Y. Assessing synchronous ovarian metastasis in gastric cancer patients using a clinical-radiomics nomogram based on baseline abdominal contrast-enhanced CT: a two-center study[J]. Cancer Imaging. 2023;23(1):71.","journal-title":"Cancer Imaging"},{"issue":"6","key":"4098_CR3","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.3892\/mco.2015.634","volume":"3","author":"F WU","year":"2015","unstructured":"WU F, ZHAO X. Clinical characteristics and prognostic analysis of Krukenberg tumor[J]. Mol Clin Oncol. 2015;3(6):1323\u20138.","journal-title":"Mol Clin Oncol"},{"issue":"5","key":"4098_CR4","doi-asserted-by":"publisher","first-page":"495","DOI":"10.3892\/mco.2016.1035","volume":"5","author":"H MATSUSHITA","year":"2016","unstructured":"MATSUSHITA H, WATANABE K. Metastatic gastric cancer to the female genital tract (Review)[J]. Mol Clin Oncol. 2016;5(5):495\u20139.","journal-title":"Mol Clin Oncol"},{"issue":"43","key":"4098_CR5","doi-asserted-by":"publisher","first-page":"6341","DOI":"10.3748\/wjg.v18.i43.6341","volume":"18","author":"JJ ZHOU","year":"2012","unstructured":"ZHOU JJ, MIAO X Y. Gastric metastasis from ovarian carcinoma: A case report and literature review[J]. World J Gastroenterology: WJG. 2012;18(43):6341\u20134.","journal-title":"World J Gastroenterology: WJG"},{"issue":"2","key":"4098_CR6","doi-asserted-by":"publisher","first-page":"138","DOI":"10.5230\/jgc.2014.14.2.138","volume":"14","author":"KIM E Y","year":"2014","unstructured":"KIM E Y, PARK C H, JUNG E S. Gastric metastasis from ovarian cancer presenting as a submucosal tumor: A case Report[J]. J Gastric Cancer. 2014;14(2):138\u201341.","journal-title":"J Gastric Cancer"},{"issue":"4","key":"4098_CR7","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.pathol.2019.03.002","volume":"51","author":"STEWART C J R","year":"2019","unstructured":"STEWART C J R, LEUNG Y C, CHAUDRY Z. Evaluation of pathology review at gynaecological oncology multidisciplinary team meetings: a 5-year prospective analysis of cases with major diagnostic discordance[J]. Pathology. 2019;51(4):353\u201361.","journal-title":"Pathology"},{"issue":"3","key":"4098_CR8","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1097\/00000478-200403000-00015","volume":"28","author":"TSUNG J S H. Institutional Pathology Consultation[J]","year":"2004","unstructured":"TSUNG J S H. Institutional Pathology Consultation[J]. Am J Surg Pathol. 2004;28(3):399.","journal-title":"Am J Surg Pathol"},{"key":"4098_CR9","unstructured":"Differentiation between ovarian. Metastasis from colorectal carcinoma and primary ovarian carcinoma: evaluation of tumour markers and mille-feuille sign on computed tomography\/magnetic resonance imaging - PubMed[EB\/OL]. [2024-12-19]. https:\/\/pubmed.ncbi.nlm.nih.gov\/31935596\/"},{"issue":"3","key":"4098_CR10","doi-asserted-by":"publisher","first-page":"178","DOI":"10.4143\/crt.2004.36.3.178","volume":"36","author":"HWANG G I","year":"2004","unstructured":"HWANG G I, YOO C H, SOHN B H. Predictive value of preoperative serum CEA, CA19-9 and CA125 levels for peritoneal metastasis in patients with gastric carcinoma[J]. Cancer Res Treat. 2004;36(3):178\u201381.","journal-title":"Cancer Res Treat"},{"key":"4098_CR11","unstructured":"Combined use of. Lysyl oxidase, carcino-embryonic antigen, and carbohydrate antigens improves the sensitivity of biomarkers in predicting lymph node metastasis and peritoneal metastasis in gastric cancer - PubMed[EB\/OL]. [2024-12-19]. https:\/\/pubmed.ncbi.nlm.nih.gov\/25060181\/"},{"key":"4098_CR12","doi-asserted-by":"crossref","unstructured":"CRISTESCU R, MOGG R, AYERS M. et. al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy[J]. Volume 362. Science; 2018. p. eaar3593. (New York, N.Y.). 6411.","DOI":"10.1126\/science.aar3593"},{"key":"4098_CR13","doi-asserted-by":"publisher","unstructured":"Tumor mutational burden (TMB). May be a promising predictive biomarker of response to PD-1\/PD-L1 targeting in MSI-H colorectal cancer. | journal of clinical Oncology[EB\/OL]. [2024-12-19]. https:\/\/doi.org\/10.1200\/JCO.2019.37.8_suppl.43","DOI":"10.1200\/JCO.2019.37.8_suppl.43"},{"issue":"10","key":"4098_CR14","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1158\/2326-6066.CIR-19-0149","volume":"7","author":"GOODMAN A M","year":"2019","unstructured":"GOODMAN A M, SOKOL E S, FRAMPTON G M. Microsatellite-Stable tumors with high mutational burden benefit from Immunotherapy[J]. Cancer Immunol Res. 2019;7(10):1570\u20133.","journal-title":"Cancer Immunol Res"},{"key":"4098_CR15","doi-asserted-by":"publisher","unstructured":"PRISMA-S: an extension to the PRISMA Statement for Reporting Literature Searches. in Systematic Reviews | Systematic Reviews | Full Text[EB\/OL]. [2025-10-10]. https:\/\/systematicreviewsjournal.biomedcentral.com\/articles\/https:\/\/doi.org\/10.1186\/s13643-020-01542-z","DOI":"10.1186\/s13643-020-01542-z"},{"issue":"2","key":"4098_CR16","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s11192-009-0146-3","volume":"84","author":"WALTMANL VAN ECK N J","year":"2010","unstructured":"VAN ECK N J WALTMANL. Software survey: VOSviewer, a computer program for bibliometric mapping[J]. Scientometrics. 2010;84(2):523\u201338.","journal-title":"Scientometrics"},{"issue":"7","key":"4098_CR17","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/jso.20739","volume":"95","author":"Y SAKAMOTO","year":"2007","unstructured":"SAKAMOTO Y, SANO T, SHIMADA K. et. al. Favorable indications for hepatectomy in patients with liver metastasis from gastric cancer[J]. J Surg Oncol. 2007;95(7):534\u20139.","journal-title":"J Surg Oncol"},{"issue":"4","key":"4098_CR18","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1016\/j.joi.2016.10.006","volume":"10","author":"L PERIANES-RODRIGUEZ A, WALTMAN","year":"2016","unstructured":"PERIANES-RODRIGUEZ A, WALTMAN L, VAN ECK N J. Constructing bibliometric networks: A comparison between full and fractional counting[J]. J Informetrics. 2016;10(4):1178\u201395.","journal-title":"J Informetrics"},{"key":"4098_CR19","unstructured":"Surgical Treatment for Patients with Krukenberg Tumor of Stomach Origin. : Clinical Outcome and Prognostic Factors Analysis | PLOS ONE[EB\/OL]. [2024-12-10]. https:\/\/journals.plos.org\/plosone\/article?id=10.1371\/journal.pone.0068227"},{"issue":"e1","key":"4098_CR20","doi-asserted-by":"publisher","first-page":"e42","DOI":"10.1136\/postgradmedj-2020-137510","volume":"98","author":"SYED M","year":"2022","unstructured":"SYED M. Krukenberg tumour[J]. Postgrad Med J. 2022;98(e1):e42.","journal-title":"Postgrad Med J"},{"key":"4098_CR21","unstructured":"Amygdalin suppresses the. proliferation, migration and EMT of gastric cancer cells by inhibiting TGF-\u03b2\/Smad signal pathway | tropical journal of pharmaceutical Research[EB\/OL]. [2025-10-10]. https:\/\/www.ajol.info\/index.php\/tjpr\/article\/view\/226199"},{"issue":"Pt A","key":"4098_CR22","doi-asserted-by":"publisher","first-page":"110887","DOI":"10.1016\/j.intimp.2023.110887","volume":"124","author":"J ZANG","year":"2023","unstructured":"ZANG J, XIAO L, SHI X. Hsa_circ_0001479 accelerates tumorigenesis of gastric cancer and mediates immune escape[J]. Int Immunopharmacol. 2023;124(Pt A):110887.","journal-title":"Int Immunopharmacol"},{"key":"4098_CR23","doi-asserted-by":"publisher","first-page":"107127","DOI":"10.1016\/j.phrs.2024.107127","volume":"202","author":"Z TANG","year":"2024","unstructured":"TANG Z, LI J, LU B. CircBIRC6 facilitates the malignant progression via miR-488\/GRIN2D-mediated CAV1-autophagy signal axis in gastric cancer[J]. Pharmacol Res. 2024;202:107127.","journal-title":"Pharmacol Res"},{"key":"4098_CR24","doi-asserted-by":"publisher","first-page":"111998","DOI":"10.1016\/j.intimp.2024.111998","volume":"132","author":"Y ZHAO","year":"2024","unstructured":"ZHAO Y, LIU Z, DENG K. et. al. Identification of TAP1 as a T-cell related therapeutic target in gastric cancer by mediating oxalipliatin-related synergistic enhancement of immunotherapy[J]. Int Immunopharmacol. 2024;132:111998.","journal-title":"Int Immunopharmacol"},{"key":"4098_CR25","doi-asserted-by":"publisher","first-page":"116120","DOI":"10.1016\/j.bcp.2024.116120","volume":"222","author":"Y ZHAO","year":"2024","unstructured":"ZHAO Y, JIANG J, ZHOU P. H3K18 lactylation-mediated VCAM1 expression promotes gastric cancer progression and metastasis via AKT-mTOR-CXCL1 axis[J]. Biochem Pharmacol. 2024;222:116120.","journal-title":"Biochem Pharmacol"},{"key":"4098_CR26","doi-asserted-by":"publisher","first-page":"113835","DOI":"10.1016\/j.intimp.2024.113835","volume":"146","author":"Z CHENG","year":"2025","unstructured":"CHENG Z, LU J, CHEN Y. The role of CD101 and Tim3 in the immune microenvironment of gastric cancer and their potential as prognostic biomarkers[J]. Int Immunopharmacol. 2025;146:113835.","journal-title":"Int Immunopharmacol"},{"key":"4098_CR27","doi-asserted-by":"publisher","unstructured":"Secondary KIYOKAWAT, Tumors, Pathology of the Ovary[M\/OL]\/\/VAN, KRIEKEN J H J. M. Encyclopedia of Pathology. Cham: Springer International Publishing, 2020: 1\u20136[2024-12-16]. https:\/\/doi.org\/10.1007\/978-3-319-28845-1_5669-1","DOI":"10.1007\/978-3-319-28845-1_5669-1"},{"issue":"4","key":"4098_CR28","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.2214\/AJR.19.22184","volume":"215","author":"M ZULFIQAR","year":"2020","unstructured":"ZULFIQAR M, KOEN J. et. al. Krukenberg tumors: update on imaging and clinical Features[J]. Am J Roentgenol. 2020;215(4):1020\u20139.","journal-title":"Am J Roentgenol"},{"key":"4098_CR29","doi-asserted-by":"publisher","unstructured":"Assessing synchronous ovarian metastasis. In gastric cancer patients using a clinical-radiomics nomogram based on baseline abdominal contrast-enhanced CT: a two-center study | cancer imaging | full Text[EB\/OL]. [2024-12-16]. https:\/\/cancerimagingjournal.biomedcentral.com\/articles\/https:\/\/doi.org\/10.1186\/s40644-023-00584-5","DOI":"10.1186\/s40644-023-00584-5"},{"issue":"1","key":"4098_CR30","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s10120-013-0259-5","volume":"17","author":"H SHIMADA","year":"2014","unstructured":"SHIMADA H, NOIE T, OHASHI M. Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the task force of the Japanese gastric cancer Association[J]. Gastric Cancer. 2014;17(1):26\u201333.","journal-title":"Gastric Cancer"},{"issue":"3","key":"4098_CR31","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1007\/s10120-003-0240-9","volume":"6","author":"Y TAKAHASHI","year":"2003","unstructured":"TAKAHASHI Y, TAKEUCHI T. The usefulness of CEA and\/or CA19-9 in monitoring for recurrence in gastric cancer patients: a prospective clinical study[J]. Gastric Cancer: Official J Int Gastric Cancer Association Japanese Gastric Cancer Association. 2003;6(3):142\u20135.","journal-title":"Gastric Cancer: Official J Int Gastric Cancer Association Japanese Gastric Cancer Association"},{"key":"4098_CR32","doi-asserted-by":"publisher","unstructured":"Clinical application of circulating tumor DNA. (ctDNA) in patients with metastatic gastric cancer. | journal of clinical Oncology[EB\/OL]. [2024-12-17]. https:\/\/doi.org\/10.1200\/JCO.2023.41.4_suppl.441","DOI":"10.1200\/JCO.2023.41.4_suppl.441"},{"issue":"11","key":"4098_CR33","doi-asserted-by":"publisher","first-page":"3382","DOI":"10.3390\/cancers12113382","volume":"12","author":"T NOGUCHI","year":"2020","unstructured":"NOGUCHI T, IWAHASHI N, SAKAI K. et. al. Comprehensive gene mutation profiling of Circulating tumor DNA in ovarian cancer: its pathological and prognostic Impact[J]. Cancers. 2020;12(11):3382.","journal-title":"Cancers"},{"issue":"2B","key":"4098_CR34","first-page":"1417","volume":"28","author":"C FAZZARI","year":"2008","unstructured":"FAZZARI C, FEDELE F, PIZZI G. Krukenberg tumour of the ovary: a case report with light microscopy, immunohistochemistry and electron microscopy study[J]. Anticancer Res. 2008;28(2B):1417\u201320.","journal-title":"Anticancer Res"},{"issue":"3","key":"4098_CR35","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1097\/01.pas.0000190787.85024.cb","volume":"30","author":"T KIYOKAWA","year":"2006","unstructured":"KIYOKAWA T, YOUNG R H, SCULLY R E. Krukenberg tumors of the ovary: a clinicopathologic analysis of 120 cases with emphasis on their variable pathologic manifestations[J]. Am J Surg Pathol. 2006;30(3):277\u201399.","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"4098_CR36","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13000-021-01079-2","volume":"16","author":"P DUNDR","year":"2021","unstructured":"DUNDR P, SINGH N. Primary mucinous ovarian tumors vs. ovarian metastases from Gastrointestinal tract, pancreas and biliary tree: a review of current problematics[J]. Diagn Pathol. 2021;16(1):20.","journal-title":"Diagn Pathol"},{"issue":"3","key":"4098_CR37","first-page":"262","volume":"3","author":"HH WONG","year":"2012","unstructured":"WONG HH. Immunohistochemical features of the Gastrointestinal tract tumors[J]. J Gastrointest Oncol. 2012;3(3):262\u201384.","journal-title":"J Gastrointest Oncol"},{"issue":"8","key":"4098_CR38","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.mpdhp.2008.06.008","volume":"14","author":"MCCLUGGAGE W G","year":"2008","unstructured":"MCCLUGGAGE W G. Immunohistochemical markers as a diagnostic aid in ovarian pathology[J]. Diagn Histopathology. 2008;14(8):335\u201351.","journal-title":"Diagn Histopathology"},{"issue":"3","key":"4098_CR39","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1093\/jjco\/hyp150","volume":"40","author":"JH SHIN","year":"2010","unstructured":"SHIN JH, BAE J H, LEE A. et. al. CK7, CK20, CDX2 and MUC2 immunohistochemical staining used to distinguish metastatic colorectal carcinoma involving ovary from primary ovarian mucinous adenocarcinoma[J]. Jpn J Clin Oncol. 2010;40(3):208\u201313.","journal-title":"Jpn J Clin Oncol"},{"issue":"4","key":"4098_CR40","doi-asserted-by":"publisher","first-page":"643","DOI":"10.3346\/jkms.2005.20.4.643","volume":"20","author":"MJ KIM","year":"2005","unstructured":"KIM MJ. The usefulness of CDX-2 for differentiating primary and metastatic ovarian carcinoma: an immunohistochemical study using a tissue microarray[J]. J Korean Med Sci. 2005;20(4):643\u20138.","journal-title":"J Korean Med Sci"},{"key":"4098_CR41","doi-asserted-by":"crossref","unstructured":"S S, K S, K A, et. al. Synchronous or metastatic gastric and ovarian malignancies: A diagnostic Challenge[J]. JOURNAL OF CLINICAL AND BIOMEDICAL SCIENCES, 2023, 13: 97\u20139.","DOI":"10.58739\/jcbs\/v13i3.23.58"},{"key":"4098_CR42","doi-asserted-by":"crossref","unstructured":"Abstract 1107. Mutant p53 increases epithelial mesenchymal transition, Estrogen receptor alpha and erbB2\/Her2\/neu | cancer research | American association for cancer research[EB\/OL]. [2024-12-17]. https:\/\/aacrjournals.org\/cancerres\/article\/70\/8_Supplement\/1107\/561390\/Abstract-1107-Mutant-p53-increases-epithelial","DOI":"10.1158\/1538-7445.AM10-1107"},{"key":"4098_CR43","doi-asserted-by":"publisher","unstructured":"Tumor Deposits. Mechanism, morphology and prognostic implications | SpringerLink[EB\/OL]. [2024-12-17]. https:\/\/link.springer.com\/book\/https:\/\/doi.org\/10.1007\/978-3-319-68582-3","DOI":"10.1007\/978-3-319-68582-3"},{"issue":"4","key":"4098_CR44","doi-asserted-by":"publisher","first-page":"041004","DOI":"10.1088\/1478-3975\/ab157a","volume":"16","author":"J ANTONY","year":"2019","unstructured":"ANTONY J, THIERY J P, HUANG R Y J. Epithelial-to-mesenchymal transition: lessons from development, insights into cancer and the potential of EMT-subtype based therapeutic intervention[J]. Phys Biol. 2019;16(4):041004.","journal-title":"Phys Biol"},{"issue":"1","key":"4098_CR45","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1080\/17512433.2022.2044790","volume":"15","author":"K HARADA","year":"2022","unstructured":"HARADA K, YAMASHITA K, IWATSUKI M. et. al. Intraperitoneal therapy for gastric cancer peritoneal carcinomatosis[J]. Expert Rev Clin Pharmacol. 2022;15(1):43\u20139.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"4098_CR46","doi-asserted-by":"publisher","unstructured":"Springer US et al. 2013: 335\u2013364[2024-12-17]. https:\/\/doi.org\/10.1007\/978-1-4614-8633-6_22","DOI":"10.1007\/978-1-4614-8633-6_22"},{"key":"4098_CR47","doi-asserted-by":"publisher","first-page":"1023314","DOI":"10.3389\/fphar.2022.1023314","volume":"13","author":"ZHOU X Q","year":"2022","unstructured":"ZHOU X Q, CHANG Y Z, SHEN C Y. Xiaoaiping injection combined with chemotherapy for advanced gastric cancer: an updated systematic review and meta-analysis[J]. Front Pharmacol. 2022;13:1023314.","journal-title":"Front Pharmacol"},{"issue":"10","key":"4098_CR48","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1097\/CAD.0000000000001379","volume":"33","author":"H TAO","year":"2022","unstructured":"TAO H, WANG C, ZHU Y. Role of Delta\/Notch-like epidermal growth factor-related receptor in gastric cancer patients and cells and its clinical significance[J]. Anticancer Drugs. 2022;33(10):1175\u201381.","journal-title":"Anticancer Drugs"},{"key":"4098_CR49","unstructured":"Erianin Regulates. PI3K\/AKT signaling pathway and inhibits cell invasion and migration in gastric cancer in Vitro[EB\/OL]. [2025-10-10]. https:\/\/www.researchgate.net\/publication\/367731047_Erianin_Regulates_PI3KAKT_Signaling_Pathway_and_Inhibits_Cell_Invasion_and_Migration_in_Gastric_Cancer_In_Vitro"},{"key":"4098_CR50","doi-asserted-by":"publisher","first-page":"1397656","DOI":"10.3389\/fphar.2024.1397656","volume":"15","author":"B LU","year":"2024","unstructured":"LU B, SHI J, CHENG T. Chemokine ligand 14 correlates with immune cell infiltration in the gastric cancer microenvironment in predicting unfavorable prognosis[J]. Front Pharmacol. 2024;15:1397656.","journal-title":"Front Pharmacol"},{"issue":"16suppl","key":"4098_CR51","doi-asserted-by":"publisher","first-page":"e16020","DOI":"10.1200\/JCO.2024.42.16_suppl.e16020","volume":"42","author":"J ANWAR","year":"2024","unstructured":"ANWAR J, ABDELHAKEEM A, KHAN M S. Survival outcomes in patients with stage IV gastric cancer with Krukenberg tumors: A systematic review and meta-analysis.[J]. J Clin Oncol. 2024;42(16suppl):e16020\u201316020.","journal-title":"J Clin Oncol"},{"issue":"15suppl","key":"4098_CR52","doi-asserted-by":"publisher","first-page":"e15563","DOI":"10.1200\/JCO.2019.37.15_suppl.e15563","volume":"37","author":"P YU","year":"2019","unstructured":"YU P, HUANG L, DU Y. Management of synchronous Krukenberg tumors from gastric cancer: A single-center experience.[J]. J Clin Oncol. 2019;37(15suppl):e15563\u201315563.","journal-title":"J Clin Oncol"},{"issue":"6","key":"4098_CR53","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1007\/s00423-022-02543-3","volume":"407","author":"T NAMIKAWA","year":"2022","unstructured":"NAMIKAWA T, MARUI A, YOKOTA K. et. al. Frequency and therapeutic strategy for patients with ovarian metastasis from gastric cancer[J]. Langenbeck\u2019s Archives Surg. 2022;407(6):2301\u20138.","journal-title":"Langenbeck\u2019s Archives Surg"},{"issue":"11","key":"4098_CR54","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.5858\/2006-130-1725-AILAKT","volume":"130","author":"AD AL-AGHA O M, NICASTRI","year":"2006","unstructured":"AL-AGHA O M, NICASTRI AD. An in-depth look at Krukenberg tumor: an overview[J]. Arch Pathol Lab Med. 2006;130(11):1725\u201330.","journal-title":"Arch Pathol Lab Med"},{"issue":"1","key":"4098_CR55","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1006\/gyno.2001.6210","volume":"82","author":"KIM H K","year":"2001","unstructured":"KIM H K, HEO D S, BANG Y J. Prognostic factors of krukenberg\u2019s tumor[J]. Gynecol Oncol. 2001;82(1):105\u20139.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"4098_CR56","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.ygyno.2005.05.028","volume":"98","author":"A AYHAN","year":"2005","unstructured":"AYHAN A, GUVENAL T, SALMAN M C. The role of cytoreductive surgery in nongenital cancers metastatic to the ovaries[J]. Gynecol Oncol. 2005;98(2):235\u201341.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"4098_CR57","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.ygyno.2004.05.007","volume":"94","author":"JH CHEONG","year":"2004","unstructured":"CHEONG JH, HYUNG W J, CHEN J. Survival benefit of metastasectomy for Krukenberg tumors from gastric cancer[J]. Gynecol Oncol. 2004;94(2):477\u201382.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"4098_CR58","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.ejso.2008.05.006","volume":"35","author":"R JIANG","year":"2009","unstructured":"JIANG R, TANG J, CHENG X. Surgical treatment for patients with different origins of Krukenberg tumors: outcomes and prognostic factors[J]. Eur J Surg Oncology: J Eur Soc Surg Oncol Br Association Surg Oncol. 2009;35(1):92\u20137.","journal-title":"Eur J Surg Oncology: J Eur Soc Surg Oncol Br Association Surg Oncol"},{"issue":"5","key":"4098_CR59","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.pap.0000213038.85704.e4","volume":"13","author":"YOUNG R H","year":"2006","unstructured":"YOUNG R H. From Krukenberg to today: the ever present problems posed by metastatic tumors in the ovary: part I. Historical perspective, general principles, mucinous tumors including the Krukenberg tumor[J]. Adv Anat Pathol. 2006;13(5):205\u201327.","journal-title":"Adv Anat Pathol"},{"issue":"8","key":"4098_CR60","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1080\/09513590701532401","volume":"23","author":"F OZDEGIRMENCI O, KAYIKCIOGLU","year":"2007","unstructured":"OZDEGIRMENCI O, KAYIKCIOGLU F. Krukenberg tumor mimicking pregnancy luteoma[J]. Gynecol Endocrinology: Official J Int Soc Gynecol Endocrinol. 2007;23(8):482\u20135.","journal-title":"Gynecol Endocrinology: Official J Int Soc Gynecol Endocrinol"},{"key":"4098_CR61","doi-asserted-by":"crossref","unstructured":"BHANKAR H, GOYAL S. TYAGI N, incidentally diagnosed Krukenberg tumor in pregnancy: A rare presentation with dismal outcome[J]. Clin Cancer Invest J, 2016, 5.","DOI":"10.4103\/2278-0513.176242"},{"issue":"18","key":"4098_CR62","first-page":"6768","volume":"61","author":"V SYED","year":"2001","unstructured":"SYED V, ULINSKI G, MOK, S C. Expression of gonadotropin receptor and growth responses to key reproductive hormones in normal and malignant human ovarian surface epithelial cells[J]. Cancer Res. 2001;61(18):6768\u201376.","journal-title":"Cancer Res"},{"key":"4098_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jsbmb.2016.02.005","volume":"158","author":"KC JEON S Y, HWANG K A, CHOI","year":"2016","unstructured":"JEON S Y, HWANG K A, CHOI KC. Effect of steroid hormones, Estrogen and progesterone, on epithelial mesenchymal transition in ovarian cancer development[J]. J Steroid Biochem Mol Biol. 2016;158:1\u20138.","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"3","key":"4098_CR64","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s00404-016-4048-3","volume":"294","author":"M KODAMA","year":"2016","unstructured":"KODAMA M, MOEINI A, MACHIDA H. Feto-maternal outcomes of pregnancy complicated by Krukenberg tumor: a systematic review of literature[J]. Arch Gynecol Obstet. 2016;294(3):589\u201398.","journal-title":"Arch Gynecol Obstet"},{"issue":"6","key":"4098_CR65","doi-asserted-by":"publisher","first-page":"799","DOI":"10.5858\/2006-130-799-MPISCC","volume":"130","author":"MD NGUYEN","year":"2006","unstructured":"NGUYEN MD, PLASIL B, WEN P. Mucin profiles in signet-ring cell carcinoma[J]. Arch Pathol Lab Med. 2006;130(6):799\u2013804.","journal-title":"Arch Pathol Lab Med"},{"issue":"1","key":"4098_CR66","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1053\/j.gastro.2023.03.008","volume":"165","author":"J CHEN","year":"2023","unstructured":"CHEN J, LIU K, LUO Y. et. al. Single-Cell profiling of tumor immune microenvironment reveals immune irresponsiveness in gastric Signet-Ring cell Carcinoma[J]. Gastroenterology. 2023;165(1):88\u2013103.","journal-title":"Gastroenterology"},{"key":"4098_CR67","first-page":"1839","volume-title":"GULER E, et. al. Past, Present, and future of serum tumor markers in management of ovarian cancer: A guide for the Radiologist[J]","author":"S RAO","year":"2021","unstructured":"RAO S, SMITH D A. GULER E, et. al. Past, Present, and future of serum tumor markers in management of ovarian cancer: A guide for the Radiologist[J]. Volume 41. Radiographics: A Review Publication of the Radiological Society of North America, Inc; 2021. pp. 1839\u201356. 6."},{"issue":"1","key":"4098_CR68","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/uog.19174","volume":"53","author":"F MORO","year":"2019","unstructured":"MORO F, PASCIUTO T. Role of CA125\/CEA ratio and ultrasound parameters in identifying metastases to the ovaries in patients with multilocular and multilocular-solid ovarian masses[J]. Ultrasound Obstet Gynecology: Official J Int Soc Ultrasound Obstet Gynecol. 2019;53(1):116\u201323.","journal-title":"Ultrasound Obstet Gynecology: Official J Int Soc Ultrasound Obstet Gynecol"},{"issue":"6","key":"4098_CR69","first-page":"581","volume":"12","author":"J ZHANG","year":"2020","unstructured":"ZHANG J, PENG P. Clinicopathological features and maternal and foetal management of pregnancy-complicating Krukenberg tumours[J]. Mol Clin Oncol. 2020;12(6):581\u20137.","journal-title":"Mol Clin Oncol"},{"key":"4098_CR70","unstructured":"Isolated Krukenberg tumor. in pregnancy - PubMed[EB\/OL]. [2024-12-18]. https:\/\/pubmed.ncbi.nlm.nih.gov\/25951735\/"},{"issue":"2","key":"4098_CR71","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S1028-4559(09)60280-1","volume":"48","author":"S SINGHAL S R, NANDA","year":"2009","unstructured":"SINGHAL S R, NANDA S, CHAUDHRY P. Metastatic bilateral malignant ovarian tumors associated with pregnancy[J]. Taiwan J Obstet Gynecol. 2009;48(2):167\u20138.","journal-title":"Taiwan J Obstet Gynecol"},{"issue":"4","key":"4098_CR72","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3810\/pgm.2013.07.2681","volume":"125","author":"M BURGAZLI K M, MERICLILER","year":"2013","unstructured":"BURGAZLI K M, MERICLILER M. Discovery of asymptomatic Krukenberg tumors diagnosed during caesarean section: therapy with hyperthermic intraperitoneal chemotherapy[J]. Postgrad Med. 2013;125(4):87\u201390.","journal-title":"Postgrad Med"},{"issue":"25","key":"4098_CR73","first-page":"7290","volume":"35","author":"G GOIDESCU I G, NEMETI","year":"2022","unstructured":"GOIDESCU I G, NEMETI G. Krukenberg tumor in pregnancy: a rare case and review of the literature[J]. the journal of Maternal-Fetal & neonatal medicine: the official journal of the European association of perinatal Medicine, the federation of Asia and Oceania perinatal societies. Int Soc Perinat Obstetricians. 2022;35(25):7290\u20135.","journal-title":"Int Soc Perinat Obstetricians"},{"key":"4098_CR74","doi-asserted-by":"publisher","first-page":"1061761","DOI":"10.3389\/fimmu.2023.1061761","volume":"14","author":"G JIANG","year":"2023","unstructured":"JIANG G, WU Q. Evaluation of immunotherapy efficacy in gynecologic cancer[J]. Front Immunol. 2023;14:1061761.","journal-title":"Front Immunol"},{"issue":"3","key":"4098_CR75","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1080\/14737159.2023.2188195","volume":"23","author":"YS YEH","year":"2023","unstructured":"YEH YS, TSAI H L, CHEN P J. Identifying and clinically validating biomarkers for immunotherapy in colorectal cancer[J]. Expert Rev Mol Diagn. 2023;23(3):231\u201341.","journal-title":"Expert Rev Mol Diagn"},{"issue":"2","key":"4098_CR76","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.ygyno.2021.09.011","volume":"163","author":"G CONTOS","year":"2021","unstructured":"CONTOS G, BACA Y. Assessment of immune biomarkers and Establishing a triple negative phenotype in gynecologic cancers[J]. Gynecol Oncol. 2021;163(2):312\u20139.","journal-title":"Gynecol Oncol"},{"issue":"4","key":"4098_CR77","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1245\/s10434-019-07812-y","volume":"27","author":"ZY Li","year":"2020","unstructured":"Li ZY, Tang L, Li ZM, et al. Four-Point computed tomography scores for evaluation of occult peritoneal metastasis in patients with gastric cancer: A Region-to-Region comparison with staging laparoscopy. Ann Surg Oncol. 2020;27(4):1103\u20139.","journal-title":"Ann Surg Oncol"},{"key":"4098_CR78","doi-asserted-by":"crossref","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial [published correction appears in Lancet. 2010;376(9749):1302]. Lancet. 2010;376(9742):687\u2013697.","DOI":"10.1016\/S0140-6736(10)61121-X"},{"issue":"10111","key":"4098_CR79","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","volume":"390","author":"YK Kang","year":"2017","unstructured":"Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10111):2461\u201371.","journal-title":"Lancet"},{"issue":"9","key":"4098_CR80","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1093\/annonc\/mdn169","volume":"19","author":"C Gravalos","year":"2008","unstructured":"Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol. 2008;19(9):1523\u20139.","journal-title":"Ann Oncol"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-04098-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-025-04098-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-04098-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T16:02:42Z","timestamp":1765296162000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-025-04098-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,9]]},"references-count":80,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4098"],"URL":"https:\/\/doi.org\/10.1186\/s12957-025-04098-1","relation":{},"ISSN":["1477-7819"],"issn-type":[{"type":"electronic","value":"1477-7819"}],"subject":[],"published":{"date-parts":[[2025,12,9]]},"assertion":[{"value":"29 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study did not involve human participants; Ethics approval was not required for this quality improvement study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"450"}}